Nine Dot

Nine Dot (stylized as 9.) is a San Francisco-based biotechnology company developing a programmable platform for the next generation of medicines. The company integrates generative artificial intelligence with high-throughput single-cell genomics to design novel therapeutic proteins and cellular systems. Founded by leaders in computational biology and genome engineering, Nine Dot aims to overcome the limitations of traditional drug discovery by creating highly specific, multi-functional biological agents. The firm is backed by top-tier investors including Arch Venture Partners, GV, and F-Prime Capital, positioning it as a significant player in the emerging field of AI-driven synthetic biology. Its approach focuses on the programmability of biology to address complex diseases in oncology and immunology.